RT Journal Article
SR Electronic
T1 A Giant Gastric Gastrointestinal Stromal Tumor Successfully Resected Following Neoadjuvant Treatment With Imatinib Mesylate
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1147
OP 1152
DO 10.21873/anticanres.14056
VO 40
IS 2
A1 RYO TAKAHASHI
A1 TAKAHIRO TOYOKAWA
A1 MAMI YOSHII
A1 TATSURO TAMURA
A1 HIROAKI TANAKA
A1 SHIGERU LEE
A1 KAZUYA MUGURUMA
A1 MASAKAZU YASHIRO
A1 MASAICHI OHIRA
YR 2020
UL http://ar.iiarjournals.org/content/40/2/1147.abstract
AB Background: Neoadjuvant treatment with imatinib mesylate (IM) has not been established for gastrointestinal stromal tumor (GIST). A case of a giant gastric GIST that was radically resected following neoadjuvant therapy with IM is reported. Case Report: A 71-year-old woman with abdominal distension was referred to our hospital for treatment. Contrast-enhanced computed tomography showed a large (>30 cm), heterogeneous mass, with dilated vessels around the tumor. The diagnosis was a gastric GIST by endoscopic ultrasound-fine needle aspiration, and neoadjuvant therapy with 400 mg IM daily was started. Radical surgery was performed after 13 months. Since the tumor was not invasive, complete resection by partial gastrectomy was achieved without the need for combined resection of other organs. The patient remains alive without recurrence 12 months after surgery. Conclusion: A giant GIST, larger than 30 cm in size, is quite rare. Neoadjuvant IM treatment should be considered in the management of large GISTs.